JAK Inhibitor Stays Effective Beyond 1 Year for Giant Cell Arteritis

By News Health
3 months Ago

(MedPage Today) — CHICAGO — Treatment of giant cell arteritis (GCA) with the oral drug upadacitinib (Rinvoq) was durably effective when continued for 2 years, results from a phase III trial extension indicated.
Some 85% of patients remained…

Source link : https://www.medpagetoday.com/meetingcoverage/acr/118147

Author :

Publish date : 2025-10-26 21:12:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

Fat Pad Injection Shows Limited Benefit for Knee OA Pain

Polyethylene Glycol Checklist May Guide Contrast Choices

Skin Reactions Uncommon but Vary by GLP-1 RAs

'People Are Taking a Sledgehammer to Patients': What We Heard This Week

Precision or Collateral Damage? Oncology's F-16 Moment

Regular Physical Activity Thwarts Fatigue, Boosts QoL in Colorectal Cancer